Compare RES & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RES | MGTX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1995 | 2018 |
| Metric | RES | MGTX |
|---|---|---|
| Price | $5.42 | $11.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $5.64 | ★ $24.57 |
| AVG Volume (30 Days) | ★ 1.3M | 744.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,919,000,000.00 | $81,391,000.00 |
| Revenue This Year | $3.29 | $141.38 |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $45.40 | ★ N/A |
| Revenue Growth | ★ 2216.21 | 144.57 |
| 52 Week Low | $4.18 | $6.62 |
| 52 Week High | $8.16 | $15.35 |
| Indicator | RES | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.34 | 45.07 |
| Support Level | $5.03 | $8.84 |
| Resistance Level | $5.70 | $11.85 |
| Average True Range (ATR) | 0.21 | 0.65 |
| MACD | -0.03 | -0.23 |
| Stochastic Oscillator | 6.36 | 7.66 |
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. Its operating segment includes Technical Services and Support Services. The Technical Services segment, which generates maximum revenue, comprises service lines that generate revenue based on equipment, personnel, or materials at the well site and are closely aligned with completion and production activities of the customers. The Support Services segment comprises service lines that generate revenue from services and equipment offered off the well site and are closely aligned with the customers' drilling activities.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.